StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their price target on shares of Trevena from $225.00 to $125.00 and set a buy rating on the stock in a report on Thursday, May 16th.

Trevena Stock Down 1.8 %

Shares of TRVN opened at $4.39 on Tuesday. The stock’s 50-day moving average price is $5.56 and its 200 day moving average price is $9.53. The firm has a market capitalization of $3.73 million, a price-to-earnings ratio of -1.64 and a beta of 1.05. Trevena has a 12-month low of $3.35 and a 12-month high of $28.00.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($9.25) by $9.02. The firm had revenue of $0.33 million for the quarter. Equities research analysts expect that Trevena will post -32.25 EPS for the current year.

Institutional Investors Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by institutional investors and hedge funds.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.